Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01103726 · ClinicalTrials.gov registry record · Phase 1
Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects
A Phase 1 study of Healthy, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 3
- Study locations
NCT01103726 is a Phase 1 study of Healthy that has completed, run by Pfizer. The registered enrollment target is 34 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT01103726, a Phase 1 study of Healthy, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 3
- Study locations
Study Summary
We hypothesize that PF-02545920 will increase glucose metabolism in a part of the brain called the striatum.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG placebo
- DRUG PF-02545920
Study Locations (3)
Connecticut
- Pfizer Investigational Site - New Haven
- Pfizer Investigational Site - New Haven
- Pfizer Investigational Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01103726
The ClinicalTrials.gov registry entry for NCT01103726 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01103726 reports 3 study locations spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT01103726 about?
NCT01103726 is a clinical study titled "Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects". We hypothesize that PF-02545920 will increase glucose metabolism in a part of the brain called the striatum.
What is the current status of trial NCT01103726?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2010-05. Estimated completion is 2011-11.
What conditions does trial NCT01103726 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT01103726?
The interventions under investigation include: Placebo (DRUG), placebo (DRUG), PF-02545920 (DRUG).
Who is sponsoring clinical trial NCT01103726?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01103726 being conducted?
This trial has 3 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.